Simplicity Solutions LLC Purchases 10,796 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Simplicity Solutions LLC increased its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 83.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,760 shares of the company’s stock after purchasing an additional 10,796 shares during the quarter. Simplicity Solutions LLC’s holdings in Maravai LifeSciences were worth $156,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in MRVI. 12 West Capital Management LP increased its position in Maravai LifeSciences by 92.2% during the 3rd quarter. 12 West Capital Management LP now owns 6,463,111 shares of the company’s stock worth $64,631,000 after purchasing an additional 3,101,275 shares in the last quarter. Braidwell LP increased its position in Maravai LifeSciences by 120.3% during the 3rd quarter. Braidwell LP now owns 3,974,857 shares of the company’s stock worth $39,749,000 after purchasing an additional 2,170,157 shares in the last quarter. Mackenzie Financial Corp increased its position in Maravai LifeSciences by 4,061.8% during the 4th quarter. Mackenzie Financial Corp now owns 2,121,161 shares of the company’s stock worth $30,354,000 after purchasing an additional 2,070,193 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Maravai LifeSciences by 32.6% during the 1st quarter. Thrivent Financial for Lutherans now owns 8,189,798 shares of the company’s stock worth $114,739,000 after purchasing an additional 2,011,683 shares in the last quarter. Finally, Norges Bank acquired a new position in Maravai LifeSciences during the 4th quarter worth approximately $28,010,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRVI. Stifel Nicolaus decreased their price target on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Craig Hallum began coverage on shares of Maravai LifeSciences in a research report on Wednesday, April 10th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Royal Bank of Canada upped their price target on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences has an average rating of “Moderate Buy” and an average target price of $11.56.

Maravai LifeSciences Trading Down 4.1 %

MRVI opened at $7.30 on Monday. Maravai LifeSciences Holdings, Inc. has a twelve month low of $4.52 and a twelve month high of $16.62. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70. The company has a fifty day moving average of $7.55 and a 200-day moving average of $6.71. The stock has a market cap of $1.84 billion, a PE ratio of -8.11 and a beta of 0.01.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $74.14 million for the quarter, compared to analyst estimates of $62.99 million. Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. On average, sell-side analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current year.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.